Nomocan Pharmaceuticals

Developing first-in-class targeted monoclonal antibody therapies for aggressive cancers

placeNew York City, New York, United States calendar_todayFounded 2014 groups4 employees language nomocan.com

Registered entities

Innovation

3 patent families (1 granted) — focus: Chemistry & metallurgy, Human necessities; filing pace slowing. Cited 560 times.

YearFilings
20191
20202
20212
20222
20231
20251

Investor mix

2 investors on record.

Investor typeCountShare
Venture capital2100%
Coming soon